LV hypertrophy seen by ECG, can prompt for further surveillance with echo.
Left ventricular hypertrophy and “strain” can play a role in the prediction of outcome with regards to the effectiveness of drug intervention to block cardiac remodeling(1,2)
The Marquette™ 12SL program differentiates between ECGs that meet only voltage criteria for left ventricular hypertrophy versus those
that meet additional criteria for LVH and/or exhibit other abnormalities that are frequently associated with LVH.(3)
Helps minimize patient data mix-ups: Automatically detects when a new patient is connected.
Reduces repeats: Immediately captures and displays the first clean, high quality waveform.